Department of Cardiology, First Affiliated Hospital of Sun Yat-Sen University, China.
NHC Key Laboratory on Assisted Circulation, Sun Yat-Sen University, China.
Eur J Prev Cardiol. 2019 Nov;26(16):1693-1706. doi: 10.1177/2047487319856733. Epub 2019 Jun 18.
Hypertensive patients are highly heterogeneous in cardiovascular prognosis and treatment responses. A better classification system with phenomapping of clinical features would be of greater value to identify patients at higher risk of developing cardiovascular outcomes and direct individual decision-making for antihypertensive treatment.
An unsupervised, data-driven cluster analysis was performed for all baseline variables related to cardiovascular outcomes and treatment responses in subjects from the Systolic Blood Pressure Intervention Trial (SPRINT), in order to identify distinct subgroups with maximal within-group similarities and between-group differences. Cox regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for cardiovascular outcomes and compare the effect of intensive antihypertensive treatment in different clusters.
Four replicable clusters of patients were identified: cluster 1 (index hypertensives); cluster 2 (chronic kidney disease hypertensives); cluster 3 (obese hypertensives) and cluster 4 (extra risky hypertensives). In terms of prognosis, individuals in cluster 4 had the highest risk of developing primary outcomes. In terms of treatment responses, intensive antihypertensive treatment was shown to be beneficial only in cluster 4 (HR 0.73, 95% CI 0.55-0.98) and cluster 1 (HR 0.54, 95% CI 0.37-0.79) and was associated with an increased risk of severe adverse effects in cluster 2 (HR 1.18, 95% CI 1.05-1.32).
Using a data-driven approach, SPRINT subjects can be stratified into four phenotypically distinct subgroups with different profiles on cardiovascular prognoses and responses to intensive antihypertensive treatment. Of note, these results should be taken as hypothesis generating that warrant further validation in future prospective studies.
高血压患者的心血管预后和治疗反应存在高度异质性。更好的分类系统,加上临床特征的表型映射,将更有助于识别发生心血管结局风险较高的患者,并为降压治疗的个体化决策提供指导。
对 SPRINT 研究中与心血管结局和治疗反应相关的所有基线变量进行无监督、数据驱动的聚类分析,以确定具有最大组内相似性和组间差异的不同亚组。采用 Cox 回归计算心血管结局的风险比(HR)及其 95%置信区间(CI),并比较不同亚组中强化降压治疗的效果。
共识别出 4 个可复制的患者亚组:亚组 1(指数高血压患者);亚组 2(慢性肾脏病高血压患者);亚组 3(肥胖高血压患者)和亚组 4(高危高血压患者)。在预后方面,亚组 4 患者发生主要结局的风险最高。在治疗反应方面,强化降压治疗仅在亚组 4(HR 0.73,95%CI 0.55-0.98)和亚组 1(HR 0.54,95%CI 0.37-0.79)中显示出获益,而在亚组 2(HR 1.18,95%CI 1.05-1.32)中与严重不良事件风险增加相关。
采用数据驱动的方法,SPRINT 研究中的受试者可分为 4 个表型上明显不同的亚组,其心血管预后和对强化降压治疗的反应各不相同。值得注意的是,这些结果应被视为产生假说的依据,需要在未来的前瞻性研究中进一步验证。